EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update

EyeGate Pharmaceuticals (NASDAQ:EYEG) a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced financial results for the twelve-month period ended December 31, 2017, and provided an update on recent corporate and operational achievements.

As quoted in the press release:

• Reported topline data from the Phase 2b clinical trial of the EGP-437 combination product for the treatment of pain and inflammation in patients having undergone cataract surgery; EGP-437 demonstrated a higher rate of success compared to vehicle at all time points, but did not show statistical significance in the trial’s co-primary endpoints;
• Reported positive topline data from the first-in-human pilot study of EyeGate Ocular Bandage Gel (OBG) in the treatment of corneal epithelial defects and submitted Investigational Device Exemption (IDE) for second pilot study;
• Awarded new U.S. patent for iontophoretic delivery of corticosteroids to the eye;

Click here to read the full press release.